Neuroblastoma Research and Treatments
Neuroblastoma Research and Treatments is a research topic within Neurology. Science Explorer counts 36k research works in it since 1950. 14.2% of them reached the world's top 10% most cited for their field and year.
This cluster of papers represents a comprehensive exploration of neuroblastoma, covering topics such as genetic mutations (including ALK and MYCN), risk classification, staging systems, immunotherapy, and genomic analysis. The research also delves into therapy strategies and prognosis for patients with neuroblastoma.
- Neuroblastoma
- ALK
- Genomic
- MYCN
- Therapy
- Risk Classification
- Immunotherapy
- Genetic Mutations
- Staging System
- Prognosis
- Research works
- 36k fractional, since 1950
- In the world top 10%
- 5.1k per year above
- Top-10% rate
- 14.2% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +20% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Neuroblastoma Research and Treatments research?
By volume, the United States and China publish the most (1.6k and 708 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.6k works
- 2 China 708 works
- 3 India 333 works
- 4 Japan 275 works
- 5 Italy 275 works
- 6 Germany 264 works
- 7 United Kingdom 179 works
- 8 France 155 works
- 9 Spain 130 works
- 10 Canada 122 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Neuroblastoma Research and Treatments research?
By volume in 2022–2025, Memorial Sloan Kettering Cancer Center publishes the most Neuroblastoma Research and Treatments research, followed by The University of Texas MD Anderson Cancer Center and All India Institute of Medical Sciences.
By volume, 2022–2025
- 1 Memorial Sloan Kettering Cancer CenterUnited States 41 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 34 works
- 3 All India Institute of Medical SciencesIndia 31 works
- 4 St. Jude Children's Research HospitalUnited States 31 works
- 5 Children's Hospital of PhiladelphiaUnited States 24 works
- 6 Capital Medical UniversityChina 21 works
- 7 Istituti di Ricovero e Cura a Carattere ScientificoItaly 21 works
- 8 University of PennsylvaniaUnited States 19 works
- 9 Stanford UniversityUnited States 17 works
- 10 Mayo Clinic in ArizonaUnited States 17 works
Who are the leading researchers in Neuroblastoma Research and Treatments?
The most-cited researchers publishing on Neuroblastoma Research and Treatments include Matthew Meyerson.
- 1 Matthew Meyerson United States 4.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Neuroblastoma Research and Treatments research done?
The largest centres of Neuroblastoma Research and Treatments research in 2022–2025 are Beijing (China), New York (United States), Shanghai (China) and Moscow (Russia). Among places with at least 20 works in it, it is an unusually large share of all research in Memphis, Heidelberg and Bethesda.
Largest cities, 2022–2025
Where it is the local speciality
- MemphisUS · 38.1 works15×
- HeidelbergDE · 42.1 works7.8×
- BethesdaUS · 46.3 works7.2×
Location quotient: how much more of its research is in Neuroblastoma Research and Treatments than the world average.
Where is the best place to study Neuroblastoma Research and Treatments?
Among universities, judged by research, Karolinska Institutet, All India Institute of Medical Sciences and Capital Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Karolinska InstitutetSweden | 61.3 | 37.3% | 4.7× | 11 | +86.0% |
| 2 | All India Institute of Medical SciencesIndia | 48.5 | 6.1% | 9.9× | 32 | -1.4% |
| 3 | Capital Medical UniversityChina | 48.3 | 17.2% | 7.1× | 21 | +41.8% |
| 4 | Baylor College of MedicineUnited States | 48.2 | 15.5% | 7.7× | 16 | +81.0% |
| 5 | Harvard UniversityUnited States | 44.3 | 24.5% | 2.6× | 17 | +53.7% |
| 6 | University of PennsylvaniaUnited States | 44.2 | 22.8% | 4.0× | 19 | +37.0% |
| 7 | Heidelberg UniversityGermany | 41.5 | 18.7% | 5.0× | 14 | +4.7% |
| 8 | Medical University of ViennaAustria | 38.6 | 11.1% | 6.6× | 10 | +35.1% |
| 9 | University of California, San FranciscoUnited States | 37.2 | 20.9% | 4.0× | 13 | +13.1% |
| 10 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 36.6 | 14.2% | 3.3× | 17 | +110.4% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Neuroblastoma Research and Treatments research growing?
Output in 2018–2022 was 20% higher than in 2013–2017, peaking in 2022. The fastest-growing topics are Neuroblastoma Research and Treatments.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.